Print this page
Home | Therapeutics | Polyplus Internal Research Programs : SIRNAPLUS™

SIRNAPLUS™

Self-delivering siRNAs for research and therapy

SIRNAPLUS site web recadrévBa SIRNAPLUS™ molecules are a family of highly innovative compounds which are able to effectively silence target genes using the RNAi mechanism. Self- delivering into cells and intrinsically able cross key biological barriers in tissue, SIRNAPLUS™ are high potential drug candidates for systemic and local administration.

plus-bleu Polyplus-transfection’s programs

Expand All Tabs

cationic siRNA seulSIRNAPLUS™ are a class of self-delivering, cationic siRNA duplexes, composed of an antisense sequence annealed to an oligospermine conjugated sense strand. There is a burining need for molecules which can safely and effective enter living cells – SIRNAPLUS™ are the solution for siRNA delivery.

  • Innovative molecules – a real alternative to nanoparticles
  • Classical building block online synthesis
  • No formulation requirements
  • Defined drug entity presenting classical pharmacology
  • Specific gene silencing activity at low nanomolar concentration
  • RISC mediated mechanism
  • Stable in serum

 

Voirin, E., Behr, JP. and Kotera M. (2007) Versatile synthesis of oligodeoxyribonucleotide-oligospermine conjugates. Nat Protoc, 2, 1360-1367.

Nothisen, M., Kotera, M., Voirin, E., Remy, JS. and Behr JP. (2009) Cationic siRNAs provide Carrier-free gene silencing in animal cells. J. Am. Chem. Soc., 131, 17730-17731.

Patent #WO 2009095887, for which Polyplus-transfection® is the worldwide exclusive licensee.

 

plus-bleu Contact us